ArticleBMJ open2026
Development of a predictive marker panel for the individualised bDMARD therapy of psoriatic arthritis: protocol for a prospective observational study (Integrate-PsA).
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPsoriatic arthritis is a chronic inflammatory disease that can affect the axial skeleton as well as the joints and enthesis. Following the failure of conventional synthetic disease-modifying antirheumatic drugs (DMARDs), numerous biological DMARDs (b-DMARDs) or targeted synthetic DMARDs are now available, although current guidelines do not recommend a specific mode of action in the absence of comorbidities or contraindications. The aim of the study is to identify markers associated with the achievement of Minimal Disease Activity (MDA) at week 16 in patients treated with tumour necrosis factor inhibitors (TNFi), interleukin-17 inhibitors (IL-17i) or interleukin-23 inhibitors (IL-23i). METHODS AND ANALYSIS: A total of 100 patients with active psoriatic arthritis (PsA) with a clinical indication for treatment escalation of methotrexate (MTX) (ie, non-response or intolerance to MTX) to a b-DMARD are to be included in the prospective observational cohort study. Patients are escalated according to physician's choice to one of the following modes of action: TNFi, IL-23i or IL-17i. Participant recruitment is currently ongoing and is expected to be completed in July 2026. This protocol was finalised prior to database lock and before any outcome analyses were conducted. The primary endpoint is achieving MDA at 16 weeks. Secondary endpoints include changes in clinical scores: Psoriasis Area and Severity Index 75% improvement, Disease Activity in Psoriatic Arthritis, Nail Psoriasis Severity Index and biomarker evaluation from blood and skin biopsy samples. Machine learning techniques will be applied to identify marker patterns associated with treatment response, while treatment-specific marker interactions will be explored on a hypothesis-generating basis. ETHICS AND DISSEMINATION: Ethics approval was obtained from the Ruhr University Bochum Ethics Committee (no. 23-7918) on 1 December 2024 for study protocol number 2.0 (30 October 2024). Study results will be published in an international journal, regardless of whether the results are positive or negative. Results will be communicated to the scientific community and healthcare professionals at the conference. TRIAL REGISTRATION NUMBER: DRKS00032573.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.